The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.
about
Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-IRespiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial CulturesConserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responsesThe cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxinInfection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidatesCirculating strains of human respiratory syncytial virus in central and south America.Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.Animal pneumoviruses: molecular genetics and pathogenesis.Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes.Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection.Identification of deletion mutant respiratory syncytial virus strains lacking most of the G protein in immunocompromised children with pneumonia in South Africa.Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response.Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity.Novel antigens for RSV vaccines.The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways.New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.Viral and host factors in human respiratory syncytial virus pathogenesis.Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease.The host response and molecular pathogenesis associated with respiratory syncytial virus infection.Paramyxoviruses infecting humans: the old, the new and the unknown.Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate.Recent advances in the development of subunit-based RSV vaccines.Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.Recent isolates of bovine respiratory syncytial virus from Britain are more closely related to isolates from USA than to earlier British and current mainland European isolates.Cloning of the transmembrane glycoproteins G and F from a Brazilian isolate of bovine respiratory syncytial virus in a prokaryotic system
P2860
Q24336258-F8950D92-1D7C-491A-A6C0-DBEE80B8F9FDQ28551477-114DE23E-E5D7-4B29-A4BD-A4475AA469C2Q33754172-E7FF6F1A-3AB8-4D64-B0BF-9BF111661523Q33863111-0CCEEACE-023C-4203-810E-7594D8208B70Q33984333-2DC8E905-FFC0-4A54-92FF-5AA9F44DFA82Q33988327-F78B4F99-434B-4BDB-A1C8-69E0A550A0FFQ34151865-F6D1B085-2F03-4C47-BAF2-8AE637827BCCQ34313560-543BA76C-B46E-412E-863E-F91CF85A9335Q34504791-8A8FD117-64DE-4A69-805D-286CA20FBE92Q34651258-5D5676D6-D9E1-41A2-91E2-94D7D2A30C16Q34825946-2911842E-04A4-4F3D-9ACF-59709311DD74Q35140383-7A223950-8371-4510-A3AC-C40EE9706EA3Q35217016-AC89A374-78A2-4BED-95B0-EBF2EF4F29EDQ35634327-C1CEBA1C-562D-4BBA-99EA-168BD5760F83Q36005960-336CBD0A-C84D-4A75-8ECC-8A956E7D4998Q36163501-0DDCAC1F-BF8A-4FF7-B789-4D3EEEBA29B7Q36237057-205FA998-5BC1-4CE6-B9D9-B3CB289D3CA7Q36483836-F8EA01DC-95C6-48F0-B1F4-FAAD8127F148Q36684360-7420EF64-DD93-457D-A232-06ADBFF30A9BQ36692791-16871013-7872-4310-8788-D54FAB710210Q37263779-6DDAC8BF-CC7D-402F-B1A2-64FA9EC31DB4Q37506512-5F0F6551-D43B-41CB-82B1-91956D9EDC62Q37596518-98E36481-545B-4E5A-A191-82A8E042E5AFQ38617302-80F93D7F-690E-4452-8E77-978D524BB39DQ45392073-4E561489-EC77-4FC8-A894-259B3C98A9E5Q45722243-D72483C0-7C77-4A59-87AE-DE1DFE90700AQ56797407-4BD838B0-B610-41EA-997D-FE9A0A8D1AB9
P2860
The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The central conserved cystine ...... infection in vitro or in vivo.
@ast
The central conserved cystine ...... infection in vitro or in vivo.
@en
The central conserved cystine ...... infection in vitro or in vivo.
@nl
type
label
The central conserved cystine ...... infection in vitro or in vivo.
@ast
The central conserved cystine ...... infection in vitro or in vivo.
@en
The central conserved cystine ...... infection in vitro or in vivo.
@nl
prefLabel
The central conserved cystine ...... infection in vitro or in vivo.
@ast
The central conserved cystine ...... infection in vitro or in vivo.
@en
The central conserved cystine ...... infection in vitro or in vivo.
@nl
P2860
P1433
P1476
The central conserved cystine ...... infection in vitro or in vivo.
@en
P2093
Michael N Teng
Peter L Collins
P2860
P304
P356
10.1128/JVI.76.12.6164-6171.2002
P407
P577
2002-06-01T00:00:00Z